

Biomarker-Based Approach to α -Synucleinopathies: Lessons from Neuropathology

Gabor G. Kovacs, MD, PhD,^{1*} Lea T. Grinberg, MD, PhD,^{2,3} Glenda Halliday, PhD,^{4,5} Irina Alafuzoff, MD, PhD,⁶ Brittany N. Dugger, PhD,⁷ Shigeo Murayama, MD,⁸ Shelley L. Forrest, PhD,¹ Ivan Martinez-Valbuena, PhD,¹ Hidetomo Tanaka, MD, PhD,¹ Tomoya Kon, MD, PhD,⁹ Koji Yoshida, MD, PhD,¹ Zane Jaunmuktane, MD, FRCPATH,¹⁰ Salvatore Spina, MD,² Peter T. Nelson, MD, PhD,¹¹ Steve Gentleman, PhD, FRCPATH,¹² Javier Alegre-Abarrategui, MD, PhD, FRCPATH,¹² Geidy E. Serrano, PhD,¹³ Vitor Ribeiro Paes, MD,³ Masaki Takao, MD, PhD,¹⁴ Koichi Wakabayashi, MD, PhD,¹⁵ Toshiki Uchihara, MD, PhD,¹⁶ Mari Yoshida, MD, PhD,¹⁷ Yuko Saito, MD, PhD,⁸ Julia Kofler, MD,¹⁸ Roberta Diehl Rodriguez, MD, PhD,¹⁹ Ellen Gelpi, MD, PhD,²⁰ Johannes Attems, MD,²¹ John F. Crary, MD, PhD,²² William W. Seeley, MD,² John E. Duda, MD,²³ C. Dirk Keene, MD, PhD,²⁴ John Woulfe, MD,²⁵ David Munoz, MD,²⁶ Colin Smith, MD,²⁷ Edward B. Lee, MD, PhD,²⁸ Manuela Neumann, MD,²⁹ Charles L. White, III, MD,³⁰ Ann C. McKee, MD,³¹ Dietmar R. Thal, MD, PhD,^{32,33} Kurt Jellinger, MD,³⁴ Bernardino Ghetti, MD,³⁵ Ian R. A. Mackenzie, MD,³⁶ Dennis W. Dickson, MD,^{37*} and Thomas G. Beach, MD, PhD, FRCPATH^{13*}

¹Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada

²Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco (UCSF), San Francisco, California, USA

³Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil

⁴Brain and Mind Centre, The University of Sydney, Sydney, Australia

⁵School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

⁶Surgical Pathology, Uppsala University Hospital, Uppsala, Sweden

⁷University of California Davis Health, Sacramento, California, USA

⁸Brain Bank for Aging Research, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

⁹Department of Neurology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

¹⁰Department of Clinical and Movement Neurosciences, Queen Square Brain Bank for Neurological Disorders, Queen Square Institute of Neurology, University College London, London, United Kingdom

¹¹Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA

¹²Imperial College London, Parkinson's UK Tissue Bank, London, United Kingdom

¹³Banner Sun Health Research Institute, Sun City, Arizona, USA

¹⁴Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry (NCNP), National Center Hospital, Tokyo, Japan

¹⁵Department of Neuropathology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

¹⁶University of Hawaii Postgraduate Medical Education Program at Okinawa Chubu Hospital, Uruma, Japan

¹⁷Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan

¹⁸Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

¹⁹Laboratório de Ressonância Magnética em Neuroradiologia (LIM-44), HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

²⁰Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria

²¹Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

²²Departments of Pathology, Neuroscience, and Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, New York, USA

²³Michael J. Crescenz VA Medical Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

²⁴Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA

²⁵Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada

²⁶St. Michael's Hospital, Toronto, Ontario, Canada

²⁷University of Edinburgh, Academic Department of Neuropathology, Centre for Clinical Brain Sciences, Edinburgh, United Kingdom

© 2024 The Author(s). *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

*Correspondence to: Dr. G.G. Kovacs, University of Toronto, Tanz Centre for Research in Neurodegenerative Disease (CRND), Krembil Discovery Tower, 60 Leonard Ave, Toronto, ON M5T 0S8, Canada; E-mail: gabor.kovacs@uhn.ca; Dr. D.W. Dickson, Department of

Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA; E-mail: dickson.dennis@mayo.edu; Dr. T.G. Beach, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA; E-mail: thomas.beach@bannerhealth.com

Relevant conflicts of interest/financial disclosures: None.

Received: 5 June 2024; **Revised:** 16 September 2024; **Accepted:** 19 September 2024

Published online 3 October 2024 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.30028

²⁸Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA

²⁹Department of Neuropathology, University Hospital Tübingen and DZNE Tübingen, Tübingen, Germany

³⁰Neuropathology Section, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA

³¹Boston University Alzheimer's Disease Center and CTE Center, Boston, Massachusetts, USA

³²Laboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU-Leuven, Leuven, Belgium

³³Department of Pathology, University Hospital Leuven, Leuven, Belgium

³⁴Institute of Clinical Neurobiology, Vienna, Austria

³⁵School of Medicine, Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana, USA

³⁶Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada

³⁷Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA

Recently, proposals have attempted to reclassify Lewy body diseases in vivo by merging the long-established clinicopathological entities of Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), and some also to include rapid eye movement (REM)-sleep behavior disorder (RBD). A position paper¹ and a personal view paper² proposed biomarker-based staging and classification of these conditions. As both papers emphasize,^{1,2} clinical diagnosis has challenges and limitations including early diagnosis that reflects the pathogenesis and clinical staging hindered by disease heterogeneity even within the same proteinopathy types. The suggested staging system is founded on the idea that diagnoses should rely on biomarkers, independent of the clinical syndrome, and the term neuronal α -synuclein disease (NSD) is proposed to redefine these conditions.¹ Together with the paper on biological classification² it was proposed that the detection of α -synuclein in cerebrospinal fluid (CSF) or skin and dopaminergic dysfunction assessed via positron emission tomography (PET) or single photon emission computed tomography (SPECT) possess the necessary sensitivity and specificity to identify the gold standard neuropathological alterations associated with Lewy body diseases.^{1,2} We welcome these initial attempts to redefine these diseases incorporating biological constructs, particularly for the early and in vivo diagnosis of these disorders. Imaging and biofluid biomarkers for neurodegeneration have potential advantages in assessing disease presence and progression during life and have made major contributions in the research setting, most notably in enriching clinical trials for Alzheimer's disease (AD). Biology-based disease definition and classification has always been a central focus of neuropathology. As noted in the original publications,^{1,2} this initial research framework will require much work to fill gaps in technology and knowledge, validate, and improve as we attempt transition from research biomarkers to disease surrogates. For example, currently α -synuclein seeding amplification assays (SAA) lack sensitivity and specificity for brain region and cell type, features known from neuropathology to be critically important to clinical outcomes. Our goal is to share the collective experience of our international group of neuropathology experts by suggesting

future research priorities to further improve the proposed research frameworks.

The first description of Lewy bodies detectable on hematoxylin and eosin staining³ and glial cytoplasmic inclusions in multiple system atrophy (MSA), observed first using Gallyas silver staining⁴ was followed by the discovery of the central role of α -synuclein, which linked these diseases together as α -synucleinopathies.⁵ Application of various anti- α -synuclein antibodies used in immunohistochemistry⁶⁻⁸ revealed a wide range of cytopathologies beyond the classical Lewy bodies, diffusely distributed in neuronal processes and the perikarya, and beyond that, in astrocytes⁹⁻¹² and oligodendroglia.^{11,13} In MSA, the pathognomonic glial cytoplasmic inclusions ("Papp-Lantos bodies")⁴ are accompanied by neuronal cytoplasmic and nuclear inclusions.¹⁴ New subtypes of MSA, where neuronal α -synuclein pathology in the limbic system is a predominant feature, have also been recognized.^{15,16}

Several genes associated with the clinical features of PD are unaccompanied by Lewy bodies on neuropathological examination. Other, not PD-related mutations and genetic conditions, including those in *PRNP* (ie, genetic prion disease),¹⁷ *APP*,¹⁸ *PSEN 1*, *PSEN 2*,¹⁹ and trisomy 21²⁰ (ie, AD-related neuropathology), infantile neurodegenerative disorders,²¹ or neurodegeneration with brain iron accumulation,²² can also show Lewy body or other types of α -synuclein pathology.

From a neuropathological viewpoint, two major categories of conditions with α -synuclein pathology can be distinguished: those where α -synuclein pathology is consistently versus inconsistently detected (Table 1). One of the latter conditions is AD. The combination of tau and α -synuclein pathology can be a foundation for disease diversity, for example, in DLB,²³ but also in AD, and that along with other factors (genetic, environmental, etc) might reflect many distinct "biological" associations, warranting unique approaches to clinical diagnosis, prevention, and therapy to aid in precision medicine. Indeed, individuals with AD and α -synuclein pathology might not necessarily have dopaminergic alterations. Even within parkinsonian disorders, many concomitant clinicopathological diagnoses exist.²⁴

TABLE 1 Conditions with α -synuclein pathology with or without SAA examinations of CSF or skin

	Seeding assay	
	CSF	Skin
α-Synuclein pathology consistently detected		
Cellular distribution: neuronal >> astroglial >> oligodendroglial		
I) PD or PDD		
• Sporadic PD	+	+
• Genetic PD (SNCA mutations)	+	n/a
• Genetic PD (certain genes)	+	n/a
• Incidental/preclinical/subclinical/premotor PD	−+	n/a
II) DLB		
• Sporadic DLB	+	+
III) Other LBD		
• “Amygdala-only” α -synuclein pathology	−+	n/a
• “Olfactory-only” α -synuclein pathology	−+	n/a
• “Periphery-only” α -synuclein pathology*	n/a	n/a
• Lewy body dysphagia	n/a	n/a
• REM sleep behavior disorder	+*	+*
• Some cases with pure autonomic failure	+	n/a
• Neuropathology confirmed brainstem only LBD	−+	n/a
Cellular distribution: oligodendroglial >> neuronal		
MSA		
I) Striatonigral degeneration (MSA-P)	+	+
II) Olivopontocerebellar atrophy (MSA-C)	+	+
III) aMSA (FTLD-synuclein)**	n/a	n/a
α-Synuclein pathology not consistently detected		
Cellular distribution: mostly neuronal		
I) Brain ageing	n/a	n/a
II) Alzheimer’s disease	−+	n/a
III) NBIA and neurometabolic disorders	n/a	n/a
III) Certain gene mutations (including <i>LRRK2</i>)	+	(<i>LRRK2</i>)

Note that results for MSA-P and MSA-C are not reported separately in the literature. Of note, skin has been used in immunofluorescence studies aimed at identifying α -synuclein pathology. However, we would like to emphasize the importance of expanding SAA studies using skin, which is already underway, to broaden the scope and reach of SAA testing.

SAA, seeding amplification assay; CSF, cerebrospinal fluid; PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; +, examination performed and positive results; n/a, data not available; −+, examination performed but low sensitivity; DLB, dementia with Lewy bodies; LBD, Lewy body disorders; REM, rapid eye movement; MSA, multiple system atrophy; MSA-P, multiple system atrophy with parkinsonism; MSA-C, multiple system atrophy with cerebellar; aMSA, atypical MSA; FTLD, frontotemporal lobar degeneration; NBIA, neurodegeneration with brain iron accumulation.

*Need to be confirmed in autopsy-based studies.

**Neuronal α -synuclein pathology predominates in the limbic system.

Novel approaches to diagnosis of α -synucleinopathy using peripheral tissues have emerged, but important caveats remain. α -Synuclein pathology is found in peripheral organs, which have been implicated as a site of initiation.²⁵ Because some studies did not find α -synuclein

pathology in the periphery without brain pathology,²⁶⁻²⁸ in contrast to another study,²⁹ current autopsy studies do not consistently support this position. Studies on peripheral organs may show variable results depending on the sampling, the processing methods, antibodies used, and

type of cohorts evaluated, including whether autopsy confirmation was included. Furthermore, the clinical implications of α -synuclein detected in nasal swab³⁰ or postmortem in the retina³¹ need to be explored.

α -Synuclein SAA has been established not only in CSF, but also in peripheral tissues such as skin. Meta-analysis on studies, most of which did not include autopsy confirmation, have shown that the pooled sensitivity and specificity to differentiate α -synucleinopathies from controls using CSF samples and SAA is high, and that overall the biological samples tested to date, the CSF and skin α -synuclein SAA have demonstrated the best diagnostic performance.³²⁻³⁴ Current CSF SAA show that α -synuclein aggregates are detectable only after α -synuclein pathology reaches a threshold in the brain. In particular, SAA CSF is less sensitive to detect α -synuclein pathology restricted to the brainstem or amygdala.³⁵⁻³⁸ Furthermore, several conditions with α -synuclein pathology defined by neuropathology are yet to be examined using in vivo α -synuclein SAA biomarkers and the most reliable method needs to be validated (Table 1).

Here, we highlight several open tasks where involvement of neuropathology can facilitate understanding the reliability of biomarkers:

- Caution is needed to consider mere detection of seeding of misfolded α -synuclein in bodily fluids or peripheral tissue as α -synucleinopathy reflecting a brain disease. Therefore, a descriptive (presence or absence of α -synuclein seeding) approach is recommended because it is not necessarily associated with neuronal degeneration and disease. For example, misfolded prion protein was reported only in the appendix in individuals who then did not develop lethal brain disease.³⁹ Longitudinal autopsy studies are necessary to determine whether stage 1 of NSD (ie, “S(+)D(-)”) or Parkinson’s type synucleinopathy (ie, “G(-)S(+)N(-)”) represent the universal first stage of brain disease. It remains unclear whether the sensitivity of the assay for low amounts of seeds might reveal a transient event, which is corrected by a functional protein clearance system hindering the pathology to progress in the brain. Furthermore, it cannot be excluded that the proteins present in the CSF (ie, inflammatory or other neurodegenerative-related proteins) can alter the outcome of the SAA, in particular that other proteinopathies co-exist frequently in LBD.⁴⁰ The reporting of seeding of misfolded α -synuclein without immunohistochemically detectable α -synuclein pathology⁴¹ warrants further investigation as well. A solution to validate the state represented by a given biomarker would be the use of additional biomarkers,⁴² ideally also confirmed by autopsy studies.
- Despite identical protofilament folds of α -synuclein,⁴³ lumping clinicopathological entities based on the presence of α -synuclein seeding alone would not decrease heterogeneity, but rather would cause misinterpretations. Neuropathology experts prioritize building classification schemes based on well-defined subtypes reflecting not only the pathoanatomical pattern, but also the co-pathologies that all might have an effect on seeding capacities.^{44,45} We recommend focusing on how biomarkers might distinguish clinicopathological conditions, including AD with α -synuclein pathology, showing different disease course and prognosis. Autopsy materials are ideally suited to facilitate developing of SAA protocols to distinguish different “strains” of α -synuclein.⁴⁶
- Indeed, some specialists advocate that Lewy body disease should be viewed as a single encompassing disease entity where phenotypic variance is caused by the presence of individual risk factors, disease mechanisms, and co-pathologies.⁴⁷ Further levels of classification will need to integrate the strain concept supported by distinct α -synuclein folds in Lewy body disease versus MSA.⁴⁸ These have relevance for SAAs based on reports claiming its ability to discriminate between samples of CSF from patients diagnosed with PD versus MSA.⁴⁹ Indeed, studies using human brain samples have demonstrated the physicochemical factors governing the in vitro amplification of α -synuclein to generate strain-specific reaction buffers.⁴⁶
- Differences in seeding from the same diseases associated with distinct proteomic profiles suggest that distinct molecular populations of α -synuclein may contribute to heterogeneity in phenotypes and progression rates.⁴⁴ This may reflect the molecular behavior of α -synuclein associated with differing prognoses (ie, duration of illness)⁴⁴ and not necessarily the pathological stage (ie, Braak stage⁵⁰ or other systems⁵¹) of protein deposition in the brain, warranting novel approaches to standardized quantification and interpretation.⁵² These concepts will need to be integrated into the interpretation of SAA results supporting better stratification of patients.
- Most of the PET or SPECT imaging meta-analyses focused on the distinction between PD and atypical parkinsonisms.^{53,54} DLB and AD with Lewy body co-pathology and cognitive predominant clinical symptoms may be associated with positive α -synuclein SAA without dopamine transporter imaging suggesting dopaminergic neurodegeneration. In combined disease forms (eg, AD with LBD) the disease pathogenesis and therapy approach might be very different.^{55,56} Indeed, recent SAA studies address this issue by combining AD biomarkers for better stratification.⁵⁷⁻⁶⁰ The addition of molecular imaging would also help with more

quantitative approaches of assessing α -synuclein pathology burden.

- SAA meta-analyses focused on examining the sensitivity and the specificity of SAA in differentiating PD from controls.^{32–34} Recent studies evaluated other conditions and show that α -synuclein assay can be useful in the diagnosis of parkinsonian disorders.⁶¹ Although this is helpful in most of the cases, in addition to AD, many atypical parkinsonism forms harbor LBD as co-pathology raising caution to attribute the clinical syndrome purely to α -synuclein disease. This well-known neuropathology observation is less integrated into the clinical practice, although it is promising that α -synuclein SAA positivity is increasingly reported in various non-PD clinical cohorts^{62,63} interpreted as concomitant proteinopathy. The presence of α -synuclein SAA positivity in the CSF in MSA⁶¹ could also lead to false interpretation as NSD¹ or Parkinson's type α -synucleinopathy² unless the SAA specifically detects MSA-associated α -synuclein, or the SAA is complemented by other tests such as neurofilament light chain.^{2,64,65}
- Additional effort is needed to incorporate pathways driving the disease in inherited parkinsonism lacking α -synuclein inclusions. Encouraging neuropathological examination for these conditions can aid in translating pathogenic markers into in vivo biomarkers.
- Most reported cohorts used as basis for the proposals do not contain the full spectrum and severity of disease/s; therefore, expanding the cohorts to additional community-based studies reflecting diversity (ie, epidemiologic neuropathology), and prioritizing full body autopsy, would be of high value. Caution is needed before concluding that CSF SAA positivity is the first detectable clinical stage of Lewy body diseases, because an insufficient number of SAA studies have been completed on skin or several gastrointestinal tract sites. Therefore, further studies^{35,36,66} are needed to correlate CSF/blood/skin α -synuclein SAA positivity with neuropathological deposition patterns in the brain and periphery.

The integration of blood-based molecular findings⁴² complemented by tissue-based bulk, single cell,⁶⁷ spatial transcriptomics,⁶⁸ proteomics,⁴⁴ imaging to detect α -synuclein in vivo,⁶⁹ genetic studies⁷⁰ reflecting pathogenic scenarios of disease, observations on the spectrum of biochemical modifications⁷¹ of the protein used as the marker of pathology (ie, α -synuclein), and anatomical overlap with other proteins⁴⁰ with potential effect on seeding⁴⁵ will pave the path for stratified medicine. Artificial intelligence-based methods for the image analysis⁷² or for the detection of novel histological subtypes of disease⁷³ with clinical relevance are also expected to expand.

We believe that these tasks need to be addressed with harmonized SAA methods and human tissue-based studies with expanded expertise, for example, as performed for the validation and the Food and Drug Administration approval of the amyloid PET tracers.⁷⁴ Although biomarkers have already contributed to clinical trial successes, there is much research to be done to ensure their appropriate and effective use in clinical settings. The neuropathology community is eager to work with our clinical and neuroimaging colleagues to achieve this important goal. ■

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

References

1. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. *Lancet Neurol* 2024;23(2):178–190.
2. Hoglinger GU, Adler CH, Berg D, et al. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. *Lancet Neurol* 2024;23(2):191–204.
3. Lewy F, Paralysis agitans I. Pathologische Anatomie. In: Lewandowsky M, Abelsdorff G, eds. *Handbuch der Neurologie*. Vol. 3. Berlin: Springer Verlag; 1912:920–933.
4. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and shy-Drager syndrome). *J Neurol Sci* 1989;94(1–3):79–100.
5. Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. *J Parkinsons Dis* 2017;7(s1):S51–S69.
6. Alafuzoff I, Parkkinen L, Al-Sarraj S, et al. Assessment of alpha-synuclein pathology: a study of the BrainNet Europe Consortium. *J Neuropathol Exp Neurol* 2008;67(2):125–143.
7. Beach TG, White CL, Hamilton RL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. *Acta Neuropathol* 2008;116(3):277–288.
8. Kovacs GG, Wagner U, Dumont B, et al. An antibody with high reactivity for disease-associated alpha-synuclein reveals extensive brain pathology. *Acta Neuropathol* 2012;124(1):37–50.
9. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. *Acta Neuropathol* 2007;114(3):231–241.
10. Kovacs GG, Breydo L, Green R, et al. Intracellular processing of disease-associated alpha-synuclein in the human brain suggests prion-like cell-to-cell spread. *Neurobiol Dis* 2014;69:76–92.
11. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. *Acta Neuropathol* 2000;99(1):14–20.
12. Altay MF, Liu AKL, Holton JL, Parkkinen L, Lashuel HA. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders. *Acta Neuropathol Commun* 2022;10(1):163.
13. Rohan Z, Milenkovic I, Lutz MI, Matej R, Kovacs GG. Shared and distinct patterns of oligodendroglial response in alpha-synucleinopathies and tauopathies. *J Neuropathol Exp Neurol* 2016;75(12):1100–1109.
14. Koga S, Dickson DW. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. *J Neurol Neurosurg Psychiatry* 2018;89(2):175–184.

15. Aoki N, Boyer PJ, Lund C, et al. Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: frontotemporal lobar degeneration associated with alpha-synuclein. *Acta Neuropathol* 2015;130(1):93–105.
16. Rohan Z, Rahimi J, Weis S, et al. Screening for alpha-synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). *Acta Neuropathol* 2015;130(2):299–301.
17. Kovacs GG, Seguin J, Quadrio I, et al. Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy. *Acta Neuropathol* 2011;121(1):39–57.
18. Halliday G, Brooks W, Arthur H, Creasey H, Broe GA. Further evidence for an association between a mutation in the APP gene and Lewy body formation. *Neurosci Lett* 1997;227(1):49–52.
19. Leverenz JB, Fishel MA, Peskind ER, et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. *Arch Neurol* 2006;63(3):370–376.
20. Ichimata S, Yoshida K, Visanji NP, Lang AE, Nishida N, Kovacs GG. Patterns of mixed pathologies in down syndrome. *J Alzheimers Dis* 2022;87(2):595–607.
21. Hatton C, Ghanem SS, Koss DJ, et al. Prion-like alpha-synuclein pathology in the brain of infants with Krabbe disease. *Brain* 2022;145(4):1257–1263.
22. Arber CE, Li A, Houlden H, Wray S. Review: insights into molecular mechanisms of disease in neurodegeneration with brain iron accumulation: unifying theories. *Neuropathol Appl Neurobiol* 2016;42(3):220–241.
23. Ferman TJ, Aoki N, Boeve BF, et al. Subtypes of dementia with Lewy bodies are associated with alpha-synuclein and tau distribution. *Neurology* 2020;95(2):e155–e165.
24. Dugger BN, Adler CH, Shill HA, et al. Concomitant pathologies among a spectrum of parkinsonian disorders. *Parkinsonism Relat Disord* 2014;20(5):525–529.
25. Borghammer P, Horsager J, Andersen K, et al. Neuropathological evidence of body-first vs. brain-first Lewy body disease. *Neurobiol Dis* 2021;161:105557.
26. Beach TG, Adler CH, Sue LI, et al. Vagus nerve and stomach synucleinopathy in Parkinson's disease, incidental Lewy body disease, and normal elderly subjects: evidence against the "body-first" hypothesis. *J Parkinsons Dis* 2021;11(4):1833–1843.
27. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. *Acta Neuropathol* 2010;119(6):689–702.
28. Jotanovic J, Milin-Lazovic J, Alafuzoff I. Gastrointestinal biopsy obtained during cancer screening, a biological marker for alpha-synucleinopathy? *J Neuropathol Exp Neurol* 2022;81(5):356–362.
29. Tanei ZI, Saito Y, Ito S, et al. Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. *Acta Neuropathol* 2021;141(1):25–37.
30. Bongianini M, Catalan M, Perra D, et al. Olfactory swab sampling optimization for alpha-synuclein aggregate detection in patients with Parkinson's disease. *Transl Neurodegener* 2022;11(1):37.
31. Hart de Ruyter FJ, Morrema THJ, den Haan J, et al. Alpha-synuclein pathology in post-mortem retina and optic nerve is specific for alpha-synucleinopathies. *NPJ Parkinsons Dis* 2023;9(1):124.
32. Grossauer A, Hemicker G, Krismer F, et al. α -Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid—a systematic review and meta-analysis. *Mov Disord* 2023;10(5):737–747.
33. Zheng Y, Li S, Yang C, Yu Z, Jiang Y, Feng T. Comparison of bio-specimens for alpha-synuclein seed amplification assays in Parkinson's disease: a systematic review and network meta-analysis. *Eur J Neurol* 2023;30(12):3949–3967.
34. Yoo D, Bang JI, Ahn C, et al. Diagnostic value of alpha-synuclein seeding amplification assays in alpha-synucleinopathies: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 2022;104:99–109.
35. Bentivenga GM, Mammana A, Baiardi S, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. *Acta Neuropathol* 2024;147(1):18.
36. Hall S, Orru CD, Serrano GE, et al. Performance of alphaSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. *Acta Neuropathol Commun* 2022;10(1):90.
37. Samudra N, Fischer DL, Lenio S, et al. Clinicopathological correlation of cerebrospinal fluid alpha-synuclein seed amplification assay in a behavioral neurology autopsy cohort. *Alzheimers Dement* 2024;20(5):3334–3341.
38. Arnold MR, Coughlin DG, Brumbach BH, et al. Alpha-synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological alpha-synuclein in the context of co-pathology and non-LBD diagnoses. *Ann Neurol* 2022;92(4):650–662.
39. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. *Acta Neuropathol* 2020;139(6):965–976.
40. Forrest SL, Kovacs GG. Current concepts of mixed pathologies in neurodegenerative diseases. *Can J Neurol Sci* 2023;50(3):329–345.
41. Kim A, Martinez-Valbuena I, Keith JL, Kovacs GG, Lang AE. Misfolded alpha-synuclein seeding is detected in suspected LRRK2-Parkinson's disease without immunohistochemically detectable alpha-synuclein pathology. *Mov Disord* 2024;39(1):218–220.
42. Hallqvist J, Bartl M, Dakna M, et al. Plasma proteomics identify biomarkers predicting Parkinson's disease up to 7 years before symptom onset. *Nat Commun* 2024;15(1):4759.
43. Yang Y, Shi Y, Schweighauser M, et al. Structures of alpha-synuclein filaments from human brains with Lewy pathology. *Nature* 2022;610(7933):791–795.
44. Martinez-Valbuena I, Swinkin E, Santamaria E, et al. Alpha-synuclein molecular behavior and nigral proteomic profiling distinguish subtypes of Lewy body disorders. *Acta Neuropathol* 2022;144(2):167–185.
45. Kon T, Ichimata S, Di Luca DG, et al. Multiple system atrophy with amyloid-beta-predominant Alzheimer's disease neuropathologic change. *Brain Commun* 2024;6(3):fcae141.
46. Martinez-Valbuena I, Visanji NP, Kim A, et al. Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy. *Transl Neurodegener* 2022;11(1):7.
47. Borghammer P, Okkels N, Weintraub D. Parkinson's disease and dementia with Lewy bodies: one and the same. *J Parkinsons Dis* 2024;14(3):383–397.
48. Lazaro DF, Lee VM. Navigating through the complexities of synucleinopathies: insights into pathogenesis, heterogeneity, and future perspectives. *Neuron* 2024;112:3029–3042.
49. Shah Nawaz M, Mukherjee A, Pritzkow S, et al. Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. *Nature* 2020;578(7794):273–277.
50. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003;24(2):197–211.
51. Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. *Acta Neuropathol* 2021;141(2):159–172.
52. Gilboa T, Swank Z, Thakur R, et al. Toward the quantification of alpha-synuclein aggregates with digital seed amplification assays. *Proc Natl Acad Sci U S A* 2024;121(3):e2312031121.
53. Kaasinen V, Vahlberg T, Stoessl AJ, Strafella AP, Antonini A. Dopamine receptors in Parkinson's disease: a meta-analysis of imaging studies. *Mov Disord* 2021;36(8):1781–1791.
54. Walker Z, Gandolfo F, Orini S, et al. Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. *Eur J Nucl Med Mol Imaging* 2018;45(9):1534–1545.
55. Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. *Nat Med* 2023;29(8):1964–1970.
56. Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. *Nat Med* 2023;29(8):1971–1978.

57. Bellomo G, Toja A, Paolini Paoletti F, et al. Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. *Alzheimers Dement* 2024;20(4):2444–2452.
58. Plastini MJ, Abdelnour C, Young CB, et al. Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra. *Ann Clin Transl Neurol* 2024;11(5):1197–1210.
59. Tosun D, Hausle Z, Iwaki H, et al. A cross-sectional study of alpha-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function. *Alzheimers Dement* 2024;20(8):5114–5131.
60. Tosun D, Hausle Z, Thropp P, et al. Association of CSF alpha-synuclein seed amplification assay positivity with disease progression and cognitive decline: a longitudinal Alzheimer's disease neuroimaging initiative study. *medRxiv* 2024.
61. Fernandes Gomes B, Farris CM, Ma Y, et al. Alpha-synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. *Parkinsonism Relat Disord* 2023;117:105807.
62. Vasilevskaya A, Martinez-Valbuena I, Anastassiadis C, et al. Misfolded alpha-synuclein in cerebrospinal fluid of contact sport athletes. *Mov Disord* 2023;38(11):2125–2131.
63. Vaughan DP, Fumi R, Theilmann Jensen M, et al. Evaluation of cerebrospinal fluid α -synuclein seed amplification assay in Progressive Supranuclear Palsy and Corticobasal Syndrome. *Mov Disord* 2024;39(12):2285–2291.
64. Martinez-Valbuena I, Visanji NP, Olszewska DA, et al. Combining skin alpha-synuclein real-time quaking-induced conversion and circulating neurofilament light chain to distinguish multiple system atrophy and Parkinson's disease. *Mov Disord* 2022;37(3):648–650.
65. Quadalti C, Calandra-Buonaura G, Baiardi S, et al. Neurofilament light chain and alpha-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes. *NPJ Parkinsons Dis* 2021;7(1):93.
66. Okuzumi A, Hatano T, Matsumoto G, et al. Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. *Nat Med* 2023;29(6):1448–1455.
67. Fiorini MR, Dillioott AA, Thomas RA, Farhan SMK. Transcriptomics of human brain tissue in Parkinson's disease: a comparison of bulk and single-cell RNA sequencing. *Mol Neurobiol* 2024.
68. Goralski TM, Meyerdirk L, Breton L, et al. Spatial transcriptomics reveals molecular dysfunction associated with cortical Lewy pathology. *Nat Commun* 2024;15(1):2642.
69. Xiang J, Tao Y, Xia Y, et al. Development of an alpha-synuclein positron emission tomography tracer for imaging synucleinopathies. *Cell* 2023;186(16):3350–3367.e3319.
70. Junker J, Lange LM, Vollstedt EJ, et al. Team science approaches to unravel monogenic Parkinson's disease on a global scale. *Mov Disord* 2024;39(10):1868–1873.
71. Zhang S, Zhu R, Pan B, et al. Post-translational modifications of soluble alpha-synuclein regulate the amplification of pathological alpha-synuclein. *Nat Neurosci* 2023;26(2):213–225.
72. Wang J, Xue L, Jiang J, et al. Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis. *NPJ Digit Med* 2024;7(1):17.
73. Kim A, Yoshida K, Kovacs GG, Forrest SL. Computer-based evaluation of alpha-synuclein pathology in multiple system atrophy as a novel tool to recognize disease subtypes. *Mod Pathol* 2024;37(8):100533.
74. Thal DR, Beach TG, Zante M, et al. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-beta pathology. *Alzheimers Dement* 2015;11(8):975–985.